And then in Diffuse Large B-cell Lymphoma there are multiple data sets attempted to generate data both to show also the impact of epcoritamab in comparison to CAR T, right?

Source: https://seekingalpha.com/article/4648639-genmab-s-gmab-q3-2023-earnings-call-transcript?source=feed_all_articles

GC012F is currently being studied in multiple investigator-initiated trials (IIT) evaluating its safety and efficacy in RRMM, newly-diagnosed multiple myeloma, and B-cell non-Hodgkin's lymphoma.

Source: https://www.marketscreener.com/quote/stock/GRACELL-BIOTECHNOLOGIES-I-117317674/news/Gracell-Biotechnologies-Announces-FDA-Clearance-of-the-IND-Application-for-Phase-1b-2-Clinical-Trial-42890341/?utm_medium=RSS&utm_content=20230203

So to make a claim that how long the B-cell aplasia, I think it's still too early.

Source: https://seekingalpha.com/article/4651389-gracell-biotechnologies-inc-grcl-q3-2023-earnings-call-transcript?source=feed_all_articles